Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 24 October 2017
Indication(s)
Aprovel is indicated in adults for the treatment of essential hypertension.
It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Cardiovascular Metabolism Knowledge Centre
The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
ESICM LIVES Highlights
ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.
Transplantation
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Fluid Management
Are you up-to-date with the latest evidence of effective procedures for fluid management?
+ 2 more
Oral Anticoagulation Reversal
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
Cushing's Syndrome
Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?
+ 2 more
Related Content
A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN)
RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of hypertensive subjects.
Added 6 months ago
SPYRAL HTN-ON MED Study
The purpose of this study is to obtain an assessment of the efficacy and safety of renal denervation in the presence of three standard antihypertensive medications.
Added 6 months ago
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)
The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension)...
Added 7 months ago
Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease? (MiLe-1)
The aim of the study is to assess the ability of Levosimendan to reduce the postoperative acute kidney...
Added 2 years ago
Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure
The purpose of this study is to evaluate the effect of levosimendan infusion, in addition to...
Added 2 years ago
Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.
Early studies suggest that radiofrequency-based renal denervation reduces blood pressure in patients with moderate hypertension. We investigated whether an alternative technology using endovascular ultrasound renal denervation...
Added 6 months ago
Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
Previous catheter-based renal denervation studies have reported variable efficacy results. We aimed to evaluate safety and blood pressure response after renal denervation or sham control in patients with uncontrolled hypertension...
Added 6 months ago
Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study
Carotid baroreflex activation lowers blood pressure and might have potential application for the treatment of resistanthypertension. We did a proof-of-principle trial with a...
Added 1 year ago
Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy.
Background and objectives: When monotherapy is inadequate for blood pressure control, the next step is either to continue monotherapy in...
Added 2 years ago
KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease aims to provide guidance on blood pressure management and treatment for...
Added 6 years ago
2013 ESH/ESC Guidelines for the management of arterial hypertension
The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) follow the guidelines jointly issued by the two societies in 2003 and 2007.
Added 5 years ago
Hypertension in adults: diagnosis and management
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over.
Added 7 years ago
More information
Category | Value |
---|---|
Agency product number | EMEA/H/C/000141 |
Orphan designation | No |
Date First Approved | 27-08-1997 |
Type | Medicinal product subject to medical prescription |
Marketing authorisation holder | Sanofi Clir SNC |